Songyang Wu
YOU?
Author Swipe
View article: Scattering characteristics of multiple Bessel vortex beams by transverse plasma flows
Scattering characteristics of multiple Bessel vortex beams by transverse plasma flows Open
This study combines the plane wave angular spectrum theory with the kinetic theory of plasmas to investigate the scattering characteristics of a macroscopic moving plasma under multi-vortex electromagnetic beam incidence. Beginning with th…
View article: A Review of Carboniferous-Triassic Tectonic-Magmatic Evolution of Luang Prabang–Loei Metallogenic Belt in Laos and Thailand and Implications for Gold–Copper Mineralization
A Review of Carboniferous-Triassic Tectonic-Magmatic Evolution of Luang Prabang–Loei Metallogenic Belt in Laos and Thailand and Implications for Gold–Copper Mineralization Open
The Luang Prabang (Laos)–Loei (Thailand) metallogenic belt is located on the northwestern margin of the Indochina Block. It is one of the most important gold–copper metallogenic belts in Southeast Asia. This region underwent tectonic and m…
View article: Identification and detection of illegal gambling websites and analysis of user behavior
Identification and detection of illegal gambling websites and analysis of user behavior Open
Illegal gambling websites use advanced technology to evade regulations, posing cybersecurity challenges. To address this, we propose a machine learning method to identify these sites and analyze user behavior accurately. The method extract…
View article: Neoadjuvant anthracycline followed by toripalimab combined with nab-paclitaxel in patients with early triple-negative breast cancer (NeoTENNIS): a single-arm, phase II study
Neoadjuvant anthracycline followed by toripalimab combined with nab-paclitaxel in patients with early triple-negative breast cancer (NeoTENNIS): a single-arm, phase II study Open
National Natural Science Foundation of China, Junshi Biosciences, and Jiangsu Hengrui Pharmaceuticals.
View article: Inversion of electron densities in plasma wakes of hypersonic targets
Inversion of electron densities in plasma wakes of hypersonic targets Open
Focusing on the plasma wakes of hypersonic targets (PWHT), this work provides a method for the inversion of electron densities in the PWHT by integrating electromagnetic radiation theory and three-wave coupling theory (TWCT). Utilizing the…
View article: Neoadjuvant Anthracycline Followed by Toripalimab Combined with Nab-Paclitaxel in Patients with Early Triple-Negative Breast Cancer (NeoTENNIS): A Single-Arm, Phase II Study
Neoadjuvant Anthracycline Followed by Toripalimab Combined with Nab-Paclitaxel in Patients with Early Triple-Negative Breast Cancer (NeoTENNIS): A Single-Arm, Phase II Study Open
View article: Inversion of Electron Densities in Plasma Wakes of Hypersonic Targets
Inversion of Electron Densities in Plasma Wakes of Hypersonic Targets Open
View article: Neoadjuvant Anthracycline Followed by Toripalimab Combined with Nab-Paclitaxel in Patients with Early Triple-Negative Breast Cancer (NeoTENNIS): A Single-Arm, Phase II Study
Neoadjuvant Anthracycline Followed by Toripalimab Combined with Nab-Paclitaxel in Patients with Early Triple-Negative Breast Cancer (NeoTENNIS): A Single-Arm, Phase II Study Open
View article: Supplementary Figure from Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial
Supplementary Figure from Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial Open
Supplementary Figure from Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial
View article: Supplementary Data from Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial
Supplementary Data from Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial Open
Supplementary Data from Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial
View article: Supplementary Table from Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial
Supplementary Table from Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial Open
Supplementary Table from Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial
View article: Supplementary Table from Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial
Supplementary Table from Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial Open
Supplementary Table from Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial
View article: Supplementary Figure from Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial
Supplementary Figure from Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial Open
Supplementary Figure from Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial
View article: Supplementary Data from Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial
Supplementary Data from Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial Open
Supplementary Data from Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial
View article: Supplementary Data from Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial
Supplementary Data from Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial Open
Supplementary Data from Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial
View article: Supplementary Data from Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial
Supplementary Data from Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial Open
Supplementary Data from Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial
View article: Supplementary Figure from Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial
Supplementary Figure from Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial Open
Supplementary Figure from Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial
View article: Data from Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial
Data from Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial Open
Purpose:Camrelizumab, an mAb against programmed cell death protein 1 (PD-1), plus nab-paclitaxel exhibited promising antitumor activity in refractory metastatic immunomodulatory triple-negative breast cancer (TNBC). Famitinib is a tyrosine…
View article: Supplementary Figure from Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial
Supplementary Figure from Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial Open
Supplementary Figure from Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial
View article: Supplementary Figure from Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial
Supplementary Figure from Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial Open
Supplementary Figure from Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial
View article: Supplementary Figure from Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial
Supplementary Figure from Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial Open
Supplementary Figure from Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial
View article: Data from Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial
Data from Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial Open
Purpose:Camrelizumab, an mAb against programmed cell death protein 1 (PD-1), plus nab-paclitaxel exhibited promising antitumor activity in refractory metastatic immunomodulatory triple-negative breast cancer (TNBC). Famitinib is a tyrosine…
View article: Measurement of the Usage of Web Clips in Underground Economy
Measurement of the Usage of Web Clips in Underground Economy Open
In this paper, we study the ecosystem of the abused Web Clips in underground economy. Through this study, we find the Web Clips is wildly used by perpetrators to penetrate iOS devices to gain profit. This work starts with 1,800 user compla…
View article: Cassiterite U-Pb age report in the Bawapin tin deposit, Tanintharyi Region, Southern Myanmar
Cassiterite U-Pb age report in the Bawapin tin deposit, Tanintharyi Region, Southern Myanmar Open
View article: 黎府构造带北部南莫溪蛇绿混杂岩的发现及其地质意义
黎府构造带北部南莫溪蛇绿混杂岩的发现及其地质意义 Open
摘要: 东南亚特提斯构造格架复杂，特别是印支板块西缘琅勃拉邦-黎府构造带构造演化及区域构造线连接更是争议不断. 通过老挝西北部填图工作，首次在黎府构造带北部南莫溪地区发现保存完整的蛇绿混杂岩，为探讨黎府构造带的属性以及区域古地理格局，选取了蛇绿混杂岩中的含放射虫硅质岩、辉长岩以及洋岛海山中的礁灰岩，开展了岩相学、古生物学、锆石LA⁃ICP⁃MS U⁃Pb年代学、岩石地球化学研究. 结果表明，该蛇绿混杂岩出露端元包括蛇纹岩、蛇纹石化橄榄岩、辉长岩、辉绿岩、玄武岩和硅质岩，蛇绿…